Trial Profile

A prospective randomized, multicentre, open label clinical trial of NovoSeven in women with severe PPH where uterotonics had failed to control the bleeding

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 26 Apr 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Eptacog alfa (Primary)
Indications Postpartum haemorrhage
Focus Therapeutic Use
Sponsors Novo Nordisk

Most Recent Events

26 Apr 2022 New trial record
22 Apr 2022 According to a Novo Nordisk media release, the company expects a final approval by the European Commission within approximately two months.
22 Apr 2022 Results published in Novo Nordisk Media Release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com